ReviewBlood2020
Overview of Castleman disease.
Review in Blood, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02817997 (ACCELERATE), which is not on this map. Cited by 279 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ACCELERATE (Advancing Castleman Care With an Electronic Longitudinal Registry, E-Repository, And Treatment/Effectiveness Research): An International Registry for Patients With Castleman Disease
Who cites it
279 citing papers in PubMed, 5 syntheses or guidelines pooled it, 439 citations in OpenAlex.
- Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease.Internal medicine journal · 2026Guideline
- Retrospective analysis of primary extranodal unicentric Castleman disease: a systematic review.Frontiers in medicine · 2026Pooled it
- Pooled it
- The clinical picture of Castleman disease: a systematic review and meta-analysis.Blood advances · 2024Pooled it
- Unicentric form of Castleman´s disease, pitfalls of diagnosis and surgical treatment.Frontiers in oncology · 2023Pooled it
- Successful treatment of idiopathic multicentric Castleman disease with TAFRO and kidney involvement: case report and literature review.Renal failure · 2026Review
- Rethinking Common Diagnoses: Idiopathic Multicentric Castleman Disease Presenting as TAFRO Syndrome: A Case Report.Clinical case reports · 2026Article
- Kidney involvement in idiopathic multicentric Castleman disease-TAFRO syndrome: clinical spectrum, pathology and outcomes.Clinical kidney journal · 2026Article
- Unicentric hyaline-vascular Castleman disease of the jejunal mesentery mimicking a gastrointestinal stromal tumor or neuroendocrine tumor: a case report.International journal of surgery case reports · 2026Article
- Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab.Pediatric blood & cancer · 2026Article
- Multidisciplinary Collaborative Treatment of Mediastinal Castleman Disease: A Case Report.The American journal of case reports · 2026Article
- The Spectrum of Human Herpesvirus 8/Epstein-Barr Virus-Co-Positive Lymphoproliferations and Lymphomas.Diseases (Basel, Switzerland) · 2026Review
- Idiopathic Multicentric Castleman Disease Associated With Seronegative Erosive Chronic Polyarthritis: A Diagnostic Challenge.Clinical case reports · 2026Article
- A Rare Case of POEMS-Associated Multicentric Castleman Disease with an Atypical Osteolytic PresentationTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026Article
- Grading of Castleman Disease Histopathology with an Attention-Based Multiple Instance Learning Model.Diagnostics (Basel, Switzerland) · 2026Article
- Diagnostic challenge of human herpesvirus 8-associated multicentric Castleman disease in a patient living with HIV disease.BMJ case reports · 2026Article
- HIV-negative KSHV/HHV8-associated multicentric Castleman disease with concurrent Kaposi sarcoma and POEMS-like manifestations.Journal of hematopathology · 2026Article
- Kikuchi-Fujimoto disease mimicking hemophagocytic lymphohistiocytosis in a young white male: a case report.Journal of medical case reports · 2026Article
- A Rare Case of Fabry Disease Combined With Idiopathic Multicentric Castleman Disease and Membranous Nephropathy.Kidney medicine · 2026Article
- Effective Use of Subcutaneous Tocilizumab in a Case of Castleman Disease Progressing From Unicentric to Multicentric Form.Journal of paediatrics and child health · 2026Article
219 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Castleman disease (CD) describes a group of at least 4 disorders that share a spectrum of characteristic histopathological features but have a wide range of etiologies, presentations, treatments, and outcomes. CD includes unicentric CD (UCD) and multicentric CD (MCD), the latter of which is divided into idiopathic MCD (iMCD), human herpes virus-8 (HHV8)-associated MCD (HHV8-MCD), and polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, skin changes (POEMS)-associated MCD (POEMS-MCD). iMCD can be further subclassified into iMCD-thrombocytopenia, ascites, reticulin fibrosis, renal dysfunction, organomegaly (iMCD-TAFRO) or iMCD-not otherwise specified (iMCD-NOS). Advances in diagnosis, classification, pathogenesis, and therapy are substantial since the original description of UCD by Benjamin Castleman in 1954. The advent of effective retroviral therapy and use of rituximab in HHV8-MCD have improved outcomes in HHV8-MCD. Anti-interleukin-6-directed therapies are highly effective in many iMCD patients, but additional therapies are required for refractory cases. Much of the recent progress has been coordinated by the Castleman Disease Collaborative Network (CDCN), and further progress will be made by continued engagement of physicians, scientists, and patients. Progress can also be facilitated by encouraging patients to self-enroll in the CDCN's ACCELERATE natural history registry (#NCT02817997; www.CDCN.org/ACCELERATE).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.